Rheumatology Medical News about pyoderma gangrenosum

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra
British Journal of Dermatology, 08/18/09

Brenner M et al. – The triad of sterile pyogenic arthritis, pyoderma gangrenosum and acne is known by the acronym of PAPA syndrome. It is a rare autosomal dominant disease of early onset. The treatment of pyoderma gangrenosum is challenging as there is often only partial response to systemic glucocorticosteroids and immunosuppressive therapies. The authors report the rapid and lasting response of pyoderma gangrenosum to the targeted treatment with the recombinant human interleukin–1 receptor antagonist (rHuIL–1Ra) anakinra in a patient with PAPA syndrome.

<< Previous
Low bone mineral density in adult patients with moderate to...

Next >>
Health information networks gain wider use

Mucocutaneous manifestations in 150 HIV-infected Indian patients and their relationship with CD4 lymphocyte counts
International Journal of STD & AIDS, 10/30/09 Relevance Score: 40%